Download presentation
Presentation is loading. Please wait.
Published byErick Jones Modified over 9 years ago
1
1 News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin) Paul Donnellan Consultant Medical Oncologist Galway University Hospitals
2
Common causes of cancer death in the United States, 2008 Rudin C M et al. Clin Cancer Res 2009;15:5622-5625 ©2009 by American Association for Cancer Research
4
4 Melanoma: Mortality
6
Tsao, H. et al. N Engl J Med 2004;351:998-1012 Clinical Images of Pigmented Lesions
7
7 Metastatic Melanoma Young age at onset Dismal prognosis –1yr survival 25%; –2yr survival 10% (Korn et al JCO 2008) Chemotherapy ineffective –Dacarbazine (DTIC) response rates 10% median survival < 8 months Never shown to improve survival
9
High Dose Interleukin-2 16% respond (6% completely and for median duration 10 yrs) 16% respond (6% completely and for median duration 10 yrs)
10
Immune ERU…
11
. Kirkwood J M et al. JCO 2008;26:3445-3455
12
Kaplan–Meier Curves for Overall Survival and Progression-free Survival in the Intention-to- Treat Population Hodi FS et al. N Engl J Med 2010;363:711-723
13
Intracellular Signaling Pathways in Melanoma Known to Be Important in the Response and Resistance to Targeted Therapy. Smalley KS, Sondak VK. N Engl J Med 2010;363:876- 878.
14
Targeting Treatment to a Specific Variant in the Melanoma Gene. McDermott U et al. N Engl J Med 2011;364:340-350.
15
Best Tumor Response for Each Patient. Chapman PB et al. N Engl J Med 2011. DOI: 10.1056/NEJMoa1103782
17
McMullan, D. M. et al. N Engl J Med 2006;354:397 A 72-year-old man presented for evaluation of progressive dyspnea and cough
18
Smoking image
21
Lung Cancer
23
Tarceva Tablet once a day Few side effects If have the target mutation, the responseto treatment is 5 times higher than withchemotherapy! 55% vs 11%
24
Crizotinib Tablet once a day Targets EML4-ALK (5% on NSCLC) Few side effects Dramatic response in patients who havefailed chemotherapy 90% patients respond Randomised Clinical Trial UCHG
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.